TY - JOUR
T1 - A new approach to ELISA-based anti-glycolipid antibody evaluation of highly adhesive serum samples
AU - Usuki, Seigo
AU - O'Brien, Dawn
AU - Rivner, Michael H.
AU - Yu, Robert K.
N1 - Funding Information:
This work was supported by a USPHS-NIH grant NS26994 and a contract from the Centers for Disease Control and Prevention to RKY. We wish to thank Ms. Quarles Brandy, research associate/coordinator for investigating clinical records of patients, and Dr. Rhea-Beth Markowitz for her editorial assistance.
PY - 2014/6
Y1 - 2014/6
N2 - The enzyme-linked immunosorbent assay (ELISA) is a standard immunoassay used in measuring antibody reactivity (expressed as titers) for glycosphingolipids (GSLs) such as gangliosides and sulfoglycolipids in the sera of patients with Guillain-Barré syndrome (GBS), variants of GBS, and chronic inflammatory demyelinating polyneuropathy (CIDP). In the present study, anti-GSL antibodies were evaluated using a new formula of affinity parametric complex (APC), calculated from limiting-dilution serum assay data, followed by affinity parametric complex criterion (APCC). Using assay results based on APCC, we analyzed serum samples categorized into acute inflammatory demyelinating polyneuropathy (AIDP), acute motor-sensory axonal neuropathy (AMSAN), CIDP, CIDP with myasthenia gravis (MG), and Amyotrophic Lateral Sclerosis (ALS). We were able to determine the affinity strength of antibodies otherwise hidden in the non-specific background activity in highly adhesive serum samples. The thin-layer chromatography (TLC)-immuno-overlay method assured us that this new method is an accurate and reliable way for evaluating anti-GSL antibodies using ELISA serum sample data.
AB - The enzyme-linked immunosorbent assay (ELISA) is a standard immunoassay used in measuring antibody reactivity (expressed as titers) for glycosphingolipids (GSLs) such as gangliosides and sulfoglycolipids in the sera of patients with Guillain-Barré syndrome (GBS), variants of GBS, and chronic inflammatory demyelinating polyneuropathy (CIDP). In the present study, anti-GSL antibodies were evaluated using a new formula of affinity parametric complex (APC), calculated from limiting-dilution serum assay data, followed by affinity parametric complex criterion (APCC). Using assay results based on APCC, we analyzed serum samples categorized into acute inflammatory demyelinating polyneuropathy (AIDP), acute motor-sensory axonal neuropathy (AMSAN), CIDP, CIDP with myasthenia gravis (MG), and Amyotrophic Lateral Sclerosis (ALS). We were able to determine the affinity strength of antibodies otherwise hidden in the non-specific background activity in highly adhesive serum samples. The thin-layer chromatography (TLC)-immuno-overlay method assured us that this new method is an accurate and reliable way for evaluating anti-GSL antibodies using ELISA serum sample data.
KW - ALS
KW - Anti-glycolipid antibody
KW - CIDP
KW - ELISA
KW - GBS
KW - Non-specific adhesions
UR - http://www.scopus.com/inward/record.url?scp=84903468987&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84903468987&partnerID=8YFLogxK
U2 - 10.1016/j.jim.2014.05.005
DO - 10.1016/j.jim.2014.05.005
M3 - Article
C2 - 24861939
AN - SCOPUS:84903468987
SN - 0022-1759
VL - 408
SP - 52
EP - 63
JO - Journal of Immunological Methods
JF - Journal of Immunological Methods
ER -